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The ubiquitin-specific protease USP7/HAUSP regu-
lates p53 and MDM2 levels, and cellular localization
of FOXO4 and PTEN, and hence is critically important
for their role in cellular processes. Here we show how
the 64 kDa C-terminal region of USP7 can positively
regulate deubiquitinating activity. We present the
crystal structure of this USP7/HAUSP ubiquitin-like
domain (HUBL) comprised of five ubiquitin-like (Ubl)
domains organized in 2-1-2 Ubl units. The last di-Ubl
unit, HUBL-45, is sufficient to activate USP7, through
binding to a ‘‘switching’’ loop in the catalytic domain,
which promotes ubiquitin binding and increases
activity 100-fold. This activation can be enhanced
allosterically by the metabolic enzyme GMPS. It
binds to the first three Ubl domains (HUBL-123) and
hyperactivates USP7 by stabilization of the HUBL-
45-dependent active state.
INTRODUCTION
The deubiquitinating enzyme (DUB) ubiquitin-specific protease 7
(USP7), also known as herpes virus-associated ubiquitin-spe-
cific protease (HAUSP), regulates the function of the tumor
suppressor p53 that is mutated or inactivated in50% of human
cancers (Vogelstein et al., 2000). USP7 removes ubiquitin from
p53 itself, but also from the p53 E3 ubiquitin-ligaseMDM2 (Cum-
mins et al., 2004; Cummins and Vogelstein, 2004; Li et al., 2002,
2004). These combined effects determine functional p53 levels,
creating an important role for USP7 in p53-dependent stress
responses (Kon et al., 2010; Marchenko et al., 2007; Meul-
meester et al., 2005). Precise regulation of USP7 expression
and activity is therefore necessary for maintaining proper cell
proliferation, and both up- and downregulation of USP7 inhibit
colon cancer cell proliferation (Becker et al., 2008). USP7 also
counteracts monoubiquitination of the transcription factor
FOXO4 oncogene, and the phosphatase PTEN tumor sup-
pressor, regulating their nuclear localization (Song et al., 2011;
Trotman et al., 2007; van der Horst et al., 2006). Consequently,
USP7 overexpression in prostate cancer was directly associatedMowith tumor aggressiveness, most likely through PTEN mislocali-
zation. Altogether, USP7 activity regulates important pathways
for cell survival, proliferation, and apoptosis, misregulation
of which often lead to tumorigenesis. Better understanding of
USP7 activity may therefore contribute to insights in the role of
these pathways in cancer.
USP7 is a cysteine isopeptidase of the ubiquitin-specific prote-
ases (USP) family (Nijman et al., 2005). It contains an N-terminal
TRAF/Math domain, a catalytic domain, and a 64 kDa C-terminal
region (Figure 1A). TheN-terminal TRAFdomain directly interacts
with the substrates of USP7 such as p53, MDM2, and TSPYL5
(Epping et al., 2011; Hu et al., 2006; Saridakis et al., 2005; Sheng
et al., 2006). The catalytic domain of USP7 has the conserved
fold of the USP family (Hu et al., 2002, 2006; Komander et al.,
2008). It shows a papain-like architecture plus an extended,
fingers-like domain that forms the ubiquitin binding pocket. Inter-
estingly, the USP7 crystal structures show that the catalytic
domain is maintained in a nonfunctional state, with the active
site residues in a nonreactive conformation. The active confor-
mation involves rearrangements of the catalytic domain that
allow ubiquitin binding and organization of the catalytic triad, as
shown in the structure of USP7 in complex with the suicide
substrate ubiquitin aldehyde (Hu et al., 2002).
The C-terminal region of USP7 is essential for effective cata-
lytic activity against a minimal synthetic substrate (Fernandez-
Montalvan et al., 2007; Ma et al., 2010). It harbors additional
MDM2 and p53 binding sites and promotes sequence-specific
DNA binding of p53 (Ma et al., 2010; Sarkari et al., 2010). It
was predicted to contain at least four domains with a ubiquitin-
like (Ubl) b-grasp fold (Zhu et al., 2007), and a NMR structure
of one of these is reported (2KVR). Ubl domains are also pre-
dicted at various positions in 16 additional USP enzymes. Two
more Ubl domain structures are available: the N-terminal
domains in USP14 (1WGG) and in USP4 (3JYU, residues 134–
222). Among theUSP family enzymes, USP7 is unique in contain-
ing a large number of consecutive Ubls.
Ubl domains share the ubiquitin fold but lack the C-terminal
Gly-Gly residues required for conjugation to a target. Although
many Ubl domains are found in the human genome, mostly
as part of multidomain proteins, only few of these have been
studied functionally (Grabbe and Dikic, 2009; Madsen et al.,
2007). Among these, distinct subclasses have different functions




Figure 1. The HUBL Domain Is Essential for USP7 Activity
(A) USP7 contains a TRAF substrate binding domain (brown), a catalytic domain (orange), and five Ubl domains (rainbow).
(B) USP7 constructs used in this study.
(C) Only in the presence of the HUBL domain can p53 be deubiquitinated. The presence of the N-terminal TRAF domain has a minor additional effect.
(D) Using 10 mM diubiquitin and 1 nM USP7, only USP7CD-HUBL is able to hydrolyse the substrate to monoubiquitin.
(E) In U2OS cells, p53 and MDM2 protein levels increase compared to control levels by overexpression of full-length USP7. However, with overexpression of
USP7N-CD, this stabilization is not observed. HSP90 was used as a loading control.
(F) Kinetic analysis of Ub-AMC hydrolysis shows similar activity for USP7FL and USP7CD-HUBL, while USP7CD is 90-fold decreased in KM/kcat. Kinetic
parameters can be found in Table S1.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPShave not yet been characterized. Moreover, since different
classes have only limited sequence similarity, they may have
very different functions.
A number of interaction partners of USP7 have been identified
(Sowa et al., 2009), but for most, neither function nor interaction
site is known. So far, the TRAF domain seems dedicated to
binding substrate proteins MDM2, p53, and TSPYL5. The
C-terminal domain is also used for interactions, as was shown
for Ataxin-1 (Hong et al., 2002) and the viral E3-ligase ICP0
(Canning et al., 2004). The metabolic enzyme GMP-synthetase
(GMPS) interacts with USP7 in Drosophila (van der Knaap
et al., 2005) and human cells (Sarkari et al., 2009). GMPS was
found upregulated in tumorigenic cells (Boritzki et al., 1981;
Weber et al., 1983) and together with USP7 is involved in cell
survival, chromatin maintenance, and transcriptional regulation
of ecdysteroid target genes (van der Knaap et al., 2010). This
interaction promotes USP7 activity toward H2B as well as
enhancing activity against p53 in Drosophila. The activation148 Molecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc.mechanism is unclear but possibly involves both general and
target-specific aspects.
Here we investigate how Ubl domains in the C-terminal region
of USP7 promote activity. We show that USP7 exists in two
states, an active and an inactive state. In the active state the
C-terminal Ubl domains HUBL-45 interact with a ‘‘switching
loop’’ in the catalytic domain. We identified point mutations
that interfere with the activation to validate its relevance in cells.
Finally we show that GMPS can allosterically stabilize the inter-
action between HUBL-45 and the catalytic domain and thus
promote the active state.
RESULTS
The HUBL Domain Is Essential for USP7 Activity In Vitro
and In Vivo
To study the function of the 64 kDa C-terminal HUBL domain
of USP7, we purified a series of different USP7 constructs
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HUBL-Dependent USP7 Activity Is Stabilized by GMPS(Figures 1A and 1B) and compared their activity against ubiquiti-
nated p53. In this assay, purified p53 was ubiquitinated in vitro
with human MDM2/MDMX and then incubated with the USP7
constructs. p53 could only be efficiently deubiquitinated by
USP7 constructs that contain the HUBL domain (Figure 1C,
top panel). Removal of the N-terminal p53-binding domain
(TRAF) does not affect the role of the HUBL domain and has
a relatively limited influence on the activity in these experiments
(Figure 1C, bottom panel).
We then analyzed the importance of the HUBL domain for
activity against ubiquitin chains, by monitoring hydrolysis of
K48-linked diubiquitin into monoubiquitin. Consistently, we
saw robust activity in the presence of the HUBL domain, where-
as in its absence no activity was observed (Figure 1D). Only when
the concentration of the catalytic domain was 1000-fold in-
creased could activity be observed (see Figure S1B available on-
line). Thus the HUBL domain is essential for full enzymatic
activity of the USP7 catalytic domain.
To study the in vivo significance of the HUBL domain, we
transfected U2OS cells with GFP-fused full-length USP7 and
USP7N-CD and investigated protein levels of two USP7
substrates, p53 and MDM2. Our experiments showed an accu-
mulation of p53 and MDM2 in the presence of full-length USP7
compared to USP7N-CD (Figure 1E). This suggests that the
HUBL domain is required to deubiquitinate p53 and MDM2,
and thereby prevents degradation, resulting in a net stabilization.
This shows that the HUBL domain is important for the activity of
USP7 in vivo and therefore essential for its biological function.
To quantify the HUBL-mediated activation, we used a minimal
synthetic substrate, ubiquitin fused to a C-terminal fluorescent
group, 7-amido-4-methylcoumarin (Ub-AMC). Full-length USP7
and a construct that lacks the TRAF domain (USP7CD-HUBL)
showed very similar activity, with similar Michaelis-Menten
kinetic parameters (Vmax 1.4 nmole s
1 and KM 3 mM) (Figure 1F
and Table S1). In contrast, the catalytic domain alone (USP7CD)
was much less active, with a decrease in Vmax to 0.06 nmole/s
(22-fold) and an increase in KM to 15 mM (5.5-fold). Altogether,
the enzyme efficiency (kcat/KM) decreases 120-fold, suggesting
that theC-terminal HUBLdomain is essential to achieve full enzy-
matic efficiency and therefore activates the catalytic domain.
Since all USP7 constructs eluted as monomers from gel filtra-
tion, it is likely that this activation occurs within the same mole-
cule. However, we wondered whether the HUBL domain could
activate the catalytic domain when it is not part of the same
chain, in trans. First we showed that the HUBL domain itself
has no DUB activity on Ub-AMC, and thenwemixed the catalytic
domain with the HUBL domain. Adding 10 mM HUBL domain to
the catalytic domain resulted in a 2-fold increase of catalytic
turnover (Figure S1A). However, when adding a higher excess
of the HUBL domain (50 mM), a clear activation can be observed
(Figure 1F). This result shows that the catalytically inactive HUBL
domain can indirectly activate the USP7 catalytic domain also in
trans, at least at high concentrations.
To exclude the possibility that the observed in vitro activation
was due to assay conditions, we tested the effect of pH and salt
concentration. The USP7 activity is strongly dependent on pH
(Figure S1C), with an optimum between pH 8 and 9, and also
shows considerable dependence on ionic strength (Figure S1D).MoSince p53 is responsible for stress responses, these pH and
ionic strength dependencies may well be relevant in cells. How-
ever, the presence of the HUBL domain has no effect on the pH
response and only a mildly positive effect on the response to salt
(Figures S1C and S1D, right panels). Thus, although activation
may have an electrostatic component, we concluded that neither
ionic strength nor pH effects explain how the activation is
achieved.
Altogether these data confirm and extend the observation
that the C-terminal domain is essential for full activity against
Ub-AMC. As expected, the N-terminal TRAF domain increases
the activity against p53, but not against the minimal target
Ub-AMC, and has therefore no effect on the HUBL activation it-
self. We thus show that the catalytically inactive HUBL domain
indirectly activates USP7 catalytic domain in a target-indepen-
dent manner.
The USP7 HUBL Structure Shows Five Ubl Domains
in Three Units
To investigate the mechanism underlying USP7 activation by its
HUBL domain, we determined the crystal structure of the HUBL
domain (residues 560–1102) using single anomalous dispersion
(SAD) phasing from selenomethionines (Figures 2A and 2B).
The final model was refined to 2.7 A˚ with Rfree of 0.216 (Table 1),
and includes residues 560–1083with no Ramachandran outliers.
The HUBL domain comprises fivemodules with the ubiquitin-like
bbabab-fold, one more than previously predicted based on
consensus fold recognition (Zhu et al., 2007). The Ubl domains
adopt an extended conformation, linked through regions of
varying size that contain either one or two a helices. The helices
connecting HUBL-2 and -3 interact with HUBL-2 (Figure S2A),
but otherwise these linkers have little contact with the individual
domains.
The Ubl domains closely resemble ubiquitin (rmsd 1.9–2.5 A˚,
Figure 2C and Figures S2B and S2C) and SUMO-2 (rmsd 2.2–
2.9 A˚), according to SSM (Krissinel and Henrick, 2004) and
DALI (Holm et al., 2008) structural similarity searches against
all structures in the PDB. Despite the structural similarities, the
sequence identities with ubiquitin are very limited, varying from
6% to 19% (Figure S2B). There are no obvious specific resem-
blances to other ubiquitin-like domains beyond the conserved
fold, and hence it is not obvious that there is a shared function
with other classes of Ubl domains.
Although the five Ubl domains share the ubiquitin fold, they are
no more similar to each other than to other ubiquitin-like struc-
tures (rmsd 2.1–2.9 A˚), and they arewidely divergent in sequence
(3%–15% sequence identity) (Figure S2B). This leads to large
variations in charge distribution, such that under physiological
conditions HUBL-1 and -2 are negatively charged (calculated
pI 4.4 and 4.5, respectively), HUBL-3 is positively charged (pI
9.8), and HUBL-4 and -5 are neutral (pI 5.6 and 6.0, respectively)
(Figure S5D). Mutations in these charged patches do not affect
the enzymatic activity of USP7 (Figure S5C), although they may
play a role in other functions of the protein, such as protein-
protein interactions with its binding partners.
The HUBL domain is organized in an elongated arrangement,
in which HUBL-3 has limited contacts with the other domains
(Figure 2B), and HUBL-1 and -2, as well as HUBL-4 and -5,lecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc. 149
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Figure 2. Crystal Structure of the HUBL Domain Shows Five Ubl Domains
(A) Secondary structure assignment of the HUBL domain. The residues are colored to the corresponding Ubl. Disordered residues (1084–1102) are boxed.
(B) Cartoon representation of the HUBL domain with surface representation of the Ubls. See Table 1 for crystallographic information.
(C) Structure superposition shows that the Ubls share the b-grasp fold with ubiquitin, with variations in the length of the loop regions (red, a helix; blue, b strand;
green, ubiquitin).
(D) Di-Ubl units HUBL-12 and HUBL-45 are somewhat similar in Ubl orientation, showing a relative 30 degree rotation of HUBL-5 compared to HUBL-2. The
ubiquitin Ile44 equivalents in the HUBL domains are labeled and depicted in sticks.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPSform di-Ubl units. Analysis with PISA (Krissinel and Henrick,
2004) shows that the di-Ubl interfaces bury a large surface
area (total1200 and740 A˚2, respectively) with negative solva-
tion energies DiG (Figure S2D), suggesting that they are stable in
solution. This was supported by the degradation pattern of semi-
purified USP7CD-HUBL, which degrades to three stable frag-150 Molecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc.ments that correspond to the masses of USP7CD-123,
USP7CD-12, andUSP7CD (Figure S2E). From this we concluded
that the HUBL domain is organized in a 2-1-2 fashion that
contains three units: HUBL-12, HUBL-3, and HUBL-45.
Structural comparison of these di-Ubl units reveals that HUBL-
12 and HUBL-45 are similarly arranged (Figure 2D). Superposing
Table 1. Crystallography Details
Data Collection Statistics HUBL (Native) HUBL (SeMet)
Wavelength (A˚) 0.873 0.979
Resolution (A˚) 2.7 3.0
Space group P212121 P212121








Rmerge (%) 7.2 (69.3) 6.2 (32.7)
I/sI 11.8 (2.0) 26.2 (7.0)
Completeness (%) 100 (99.9) 99.5 (97.0)
Redundancy 4.5 (4.6) 13.1 (12.8)
Refinement
Unique reflections (#) 27,939 20,203
Protein atoms (#) 4,340
Waters (#) 129
Rwork/Rfree (%) 19.1/21.6






Highest-resolution shell is shown in parentheses.
aCalculated using MolProbity.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPSthe N-terminal domains HUBL-1 and HUBL-4 shows that equiv-
alent interfaces are buried on the first Ubl in each pair, including
the residue that is equivalent to the canonical Ile-44 of ubiquitin
(Trp-623 and Leu-942, respectively). The second Ubl domains
do not bury their Ile-44 equivalent residues (Tyr 735 and Ala
1041), and they are arranged slightly differently with a relative
rotation of 30 degrees resulting in small differences in detailed
contacts. In both di-Ubl units the interfaces are mediated by
extensive hydrophobic contacts as well as hydrogen bonds
and electrostatic interactions (Figure S2D). This suggests that
these di-Ubl units are functionally relevant.
SAXS Analysis Suggests Flexibility and Interaction
between USP7CD and HUBL
Wewere intrigued by the extended structure of theHUBLdomain
and wondered whether it was relevant in solution. To address
this question, we used small-angle X-ray scattering (SAXS).
When we compared SAXS curves recorded for the USP7CD,
HUBL-123, and HUBL-45 domains to scattering curves calcu-
lated from their corresponding crystal structures, we obtained
a good fit between the experimental and calculated curves (Fig-
ure 3A). The calculated molecular weights (Mw), radii of gyration
(Rg), and maximum interatomic distance (Dmax) also corre-
spond well with the expected values (Figure 3B), with only the
Rg of HUBL-45 30% larger than expected from the structure.
These data show that USP7CD, HUBL-123, and HUBL-45 are
structurally stable subdomains of USP7 also in solution.
In contrast, the scattering curve for the complete HUBL
domain does not fit the calculated scattering curve (Figure 3A).MoThe interatomic distance probability distribution P(r) shows a
nonsymmetrical shape, including a significant proportion of
long distances (Figure 3C). This suggests that the extended
conformation is retained in solution. Since rigid body modeling
did not yield a single model, we conclude that the structure of
the HUBL domain in solution is not static, most likely exhibiting
considerable flexibility between the two stable domains,
HUBL-123 and HUBL-45.
The HUBL domain and USP7CD-HUBL have a similar radius,
with the HUBL domain being marginally smaller as expected
(Figures 3B and 3C). However, in the USP7CD-HUBL domain
P(r) plot (Figure 3C) the asymmetry due to long interatomic
distances mostly disappears, indicating a more compact mole-
cule, despite the addition of the catalytic domain. This suggests
that the HUBL domain folds back to the catalytic domain, result-
ing in a more compact shape. Since rigid body modeling did not
yield a single solution, the interaction between the catalytic
domain and the HUBL domain could be dynamic.
HUBL-45 Is Sufficient for USP7 Activation
To identify theminimal region in theHUBLdomain that is required
for activation of the USP7 enzymatic activity, we produced
C-terminal deletion constructs (Figure 1B). Upon deletion of the
last one or two Ubl domains, the resulting USP7CD-1234 and
USP7CD-123 has a severely compromised catalytic turnover,
similar to the catalytic domain alone (Figure 4A). As HUBL-45 is
an independent folding unit that seemed essential for in vitro
activity, we tested if deleting it would affect USP7 function in vivo.
After transfecting U2OS cells with full-length USP7, USP7N-
CD, or USP7N-CD-123, we monitored p53 and MDM2 protein
levels. Our experiments showed an accumulation of p53 and
MDM2 in the presence of the full-length USP7, which is not
observed in absence of HUBL-45 (USP7N-CD-123) (Figure 4B),
suggesting that it is required to deubiquitinate p53 and MDM2.
This shows that HUBL-45 is essential for USP7 function in vivo.
Thenwe analyzedwhether HUBL-45 alone is enough to recon-
stitute full activity. We deleted HUBL-123, coupling the HUBL-45
unit directly to the catalytic domain via a 2 amino acid linker
(USP7CD-45). This variant had Vmax and KM values almost iden-
tical to the complete USP7CD-HUBL (Figure 4D) in the Ub-AMC
assay. In addition, USP7CD-HUBL and USP7CD-45 have similar
efficiency against a diubiquitin substrate (Figure 4C). These
results show that HUBL-45 is sufficient to reconstitute the
USP7 activation.
HUBL-45 consists of the di-Ubl unit and a flexible C-terminal
19 residue peptide that is disordered in the crystal structure.
When we deleted this C-terminal tail of HUBL-45 (USP7CD-
45DC) we observed a greatly reduced activity, similar to
USP7CD (Figure 4A), showing that the C-terminal peptide is crit-
ical for the activation. To see whether this peptide alone was
sufficient to promote activation, we performed in trans activation
experiments with Ub-AMC using the peptide alone versus
complete HUBL-45, including the peptide. In these assays (Fig-
ure S3A), the peptide marginally activates USP7CD in trans,
whereas the full HUBL-45 domain provides robust levels of
activation (Figure S3A). Therefore, we conclude that the
C-terminal activation peptide is essential to increase the activity
of USP7CD, but only in the context of HUBL-45.lecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc. 151
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Figure 3. SAXS Analysis of the HUBL Domain
(A) Scattering curves of the USP7 fragments (red symbols) with corresponding scattering curves calculated from the crystal structures (black lines).
(B) Overview of the SAXS analysis results.
(C) The symmetrical interatomic distance probability distribution (P(r)) of USP7CD-HUBL shows that it has less extended shape than the HUBL domain, indicating
that the HUBL domain folds back onto the CD.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPSCollectively, the activation of the catalytic domain and the
SAXS data imply that the activation mechanism is through a
direct interaction between the catalytic domain and HUBL-45.
Indeed, when using a surface plasmon resonance (SPR) binding
assay with immobilized GST-USP7CD, we observed a 50 mM
dissociation constant (Kd) for HUBL-45 (Figure 4E), in agreement
with the concentrations required for trans activation by the
HUBL domain (Figure 1F and Figure S3A). When the flexible
C-terminal peptide was removed (HUBL-45DC), the affinity for
the catalytic domain did not change (Figure 4E). Since no binding
was detected between the catalytic domain and the peptide
(Figure S3B), we concluded that although the peptide is essential
for activity, the HUBL-45 di-Ubl unit is required for binding
to the catalytic domain. This brings the flexible C-terminal
activation peptide close to the catalytic domain, resulting in its
activation.
The HUBL Domain Promotes Ubiquitin Binding
When considering the mechanism of USP7 activation, we real-
ized that the lower KM value in the catalytically efficient con-
structs suggested an increase in substrate affinity. Therefore
we tested whether the HUBL domain affected the ubiquitin
affinity of USP7CD. We incubated with the suicide substrate
ubiquitin-VME (20 mM) (Borodovsky et al., 2001). While USP7CD152 Molecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc.alone was loaded only partially, USP7CD-45 loading was essen-
tially complete (Figure S4A).
Since this could indicate an increase of ubiquitin affinity, we
decided to validate this by SPR experiments. Neither USP7CD
nor USP7CD-12 shows appreciable ubiquitin binding, with
almost no responses measured up to 17 mM, suggesting very
little affinity for ubiquitin (Figure 5A and Figure S4B). Also, no
ubiquitin binding was observed for the HUBL domain itself
(Figure 5A). However, the catalytically efficient USP7CD-HUBL
construct showed a clear association and dissociation from
ubiquitin. Both the kinetic and equilibrium data could be fitted
with a Kd of 1.5 mM (Figures 5B and 5E). This indicates that the
catalytic and HUBL domains cooperate to achieve ubiquitin
binding. USP7CD-45 also binds ubiquitin with a Kd of 4 mM,
similar to USP7CD-HUBL (Figures 5C and 5E), confirming that
HUBL-45 is sufficient for the activation of USP7. Interestingly,
although these Ubl domains may resemble ubiquitin, they do
not compete for ubiquitin binding to USP7. Instead, they pro-
mote this interaction.
In the kinetic analyses, we observed that the catalytic domain
and the HUBL domain cooperate in trans (Figure 1F). To test if
that also translates to ubiquitin binding, different concentrations
of USP7CD were flowed over the GST-ubiquitin chip in the pres-
ence of 50 mM HUBL. A partial reconstitution of the ubiquitin
A B C
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Figure 4. HUBL-45 Is Sufficient for Activation
(A) Any C-terminal deletion reduces activity to similar levels as USP7CD in Ub-AMC assays. However, the USP7CD-45 construct showed activity similar to that of
USP7CD-HUBL. Removing the C-terminal peptide (USP7CD-45DC) resulted in greatly reduced activity.
(B) Loss of HUBL-45 reduces USP7 activity in U2OS cells: protein levels of p53 and MDM2 did not increase as seen with the wild-type full-length USP7. HSP90
was used as a loading control.
(C) USP7CD-HUBL and USP7CD-45 have similar activity toward 10 mM diubiquitin (K48), while USP7CD did not show any activity.
(D) USP7CD-45 still showed full activity in Ub-AMC assays.
(E) SPR binding experiments show an interaction with a Kd of 50 (±11) mM between GST-USP7CD and HUBL-45.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPSbinding to a Kd of 13 mM was achieved, confirming that trans
activation of the catalytic domain translates in an increased ubiq-
uitin affinity (Figures 5D and 5E). The observed ubiquitin affinities
correlate with the KM values for Ub-AMC derived in the kinetic
analysis, and therefore show that the increase of KM can be
explained by the increase of Kd (Table S1).
Point Mutants Prevent HUBL Autoactivation
To understand how HUBL-45 conveys the activation to the cata-
lytic domain, we used site-directed mutagenesis and tested
a number of different options (Figure S5). In USP7 the residues
forming the catalytic triad adopt an inactive conformation (Hu
et al., 2002) (Figure S5A). However, upon ubiquitin binding, the
active site is remodeled to the active conformation. With this
conformational change a small loop close to the active site (resi-
dues 285–291), that we name ‘‘switching loop,’’ shows dramatic
changes (Figure 6A).
We mutated several residues in this switching loop, in the
context of both USP7CD and USP7CD-45, and tested their
activity using Ub-AMC (Figure 6B and Table S1). These muta-
tions show a limited activating effect when tested in the catalytic
domain alone. However, in the context of USP7CD-45, twoMoswitching loop mutants, W285D and E286A, greatly reduce the
activation effect conferred by HUBL-45. Moreover, the W285D
E286A double mutant has a greatly reduced ubiquitin affinity
(Figure 6D and Figures S4C and S4D).
The 19 residues in the flexible C-terminal peptide of HUBL-45
are essential for the activation (Figure S3A and Figure 6C).
Several single-point mutants of conserved residues displayed
a reduction in activating capacity (Figure 6C). Strikingly, the
single-point mutant I1100S completely abolished the HUBL
activation and greatly reduced ubiquitin binding (Figure 6C, Fig-
ure S4D, and Table S1). Consistently, overexpressing these
USP7 mutants in U2OS cells completely abolished the stabiliza-
tion of p53 and MDM2 observed for the wild-type enzyme (Fig-
ure 6E). This shows that, although they are not in direct contact
with ubiquitin, both the switching loop and the C-terminal
peptide of the HUBL domain are required for the HUBL-medi-
ated increase of activity and ubiquitin affinity.
GMPS Binds to HUBL-123 and Allosterically Promotes
Activation
Due to the intrinsic flexibility and weak interactions with the





Figure 5. Ubiquitin Affinity Is Increased by the HUBL Domain
(A) SPR binding studies using GST-tagged ubiquitin showed weak ubiquitin binding for USP7CD and no responses with the HUBL domain.
(B) USP7CD-HUBL binds to ubiquitin, which could be fitted using the binding kinetics (black line) to a Kd 1.5 (±0.5) mM. The inset shows the residuals.
(C) USP7CD-45 binds ubiquitin with a dissociation constant of 4.15 (±0.6) mM. The inset shows the residuals.
(D) The dissociation constant for ubiquitin of the USP7CD is increased to 12.90 (±1.4) mM in the presence of 50 mM of the HUBL domain.
(E) Overlay of the normalized equilibrium responses.
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HUBL-Dependent USP7 Activity Is Stabilized by GMPSactivated state. Therefore, the HUBL activation mechanism may
be susceptible to regulation. A prime candidate for this regula-
tion is GMPS, a metabolic enzyme that binds and activates
USP7 in Drosophila (van der Knaap et al., 2005) and humans
(Sarkari et al., 2009). To analyzewhether theHUBL domain intrin-
sically and constitutively activates USP7, or whether it can be
further regulated, we studied the modulation of USP7 activity
by GMPS.
First, we wondered which USP7 domains are involved in
GMPS binding. Using pull-down experiments with various
GST-tagged USP7 constructs, we show that GMPS binds to
USP7 only when HUBL-123 is present (Figure S7A). USP7CD-
HUBL, USP7CD-123, and HUBL-123 have a very tight interac-
tion with GMPS (Kd of 30–40 nM), as shown by SPR (Figure 7A
and Figures S7B and S7C). Neither USP7CD nor USP7CD-45
showed any appreciable binding to GMPS (Figure 7A and154 Molecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc.Figure S7C), confirming that HUBL-123 is sufficient for the
USP7-GMPS interaction.
Next, we wanted to see if GMPS binding affects USP7 activity.
Indeed, the activity of USP7CD-HUBL in Ub-AMC assays is
increased 5.5-fold in the presence of GMPS (Figure 7B and Table
S1). Kinetic analysis reveals an increased kcat, with only a slightly
increased KM, consistent with the observation that the ubiquitin
affinity of the complex does not change (Kd 2.5 ± 0.17 mM) (Fig-
ure S7D). The presence of GMPS does not activate USP7CD-
123 even if they interact tightly (Figure S7E). Importantly, when
we introduced the W285D E286A and I1100S mutations to
USP7CD-HUBL, the mutant proteins bound GMPS equally well
as the wild-type (Figures S7A–S7C) but could no longer be acti-
vated by GMPS (Figure 7C). This shows that GMPS hyperactiva-
tion of USP7 requires a functional switching loop in the catalytic




Figure 6. Mutants in the Catalytic Domain and HUBL-45 Prevent Activation
(A) Crystal structures of the USP7 catalytic domain (1NB8 and 1NBF) show a remodeling of the switching loop (residuesW285–F291) and active site upon binding
of ubiquitin aldehyde. Schematic diagram of USP7CD-45 shows catalytic residues, the switching loop, and activation peptide.
(B) Mutating switching loop residues W285 and E286 in the catalytic domain dramatically reduced the activity of USP7CD-45. In USP7CD a limited activating
effect is seen, due to destabilization of the inactive form. Mutating F291 resulted in extra HUBL activation. The activity is normalized to full-length USP7.
(C) Mutating conserved residues in the C-terminal activation peptide of HUBL-45 resulted in decreased activity on Ub-AMC, with a complete loss of activation for
mutant Ile1100Ser.
(D) SPR shows dramatic decrease in ubiquitin binding for USP7CD-45 W285D E286A (Kd = 67.9 ± 5.3 mM).
(E) USP7FL activity in U2OS cells is reduced for mutants in the switching loop (1,W285D E286A) or in the activation peptide (2,DC; 3, I1100S), since protein levels
of p53 and MDM2 only increase with wild-type USP7. HSP90 was used as a loading control.
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Figure 7. GMPS Can Hyperactivate the HUBL Autoactivation
(A) SPR experiments show that GMPS binds to USP7 constructs containing HUBL-123 with a Kd of 30–40 nM.
(B) Kinetic analysis of USP7CD-HUBL / GMPS complex showed a 5.5-fold increase of kcat.
(C) The W285D E286A and I1100S mutants in USP7CD-HUBL (solid lines) prevent hyperactivation by GMPS (dashed lines) in the Ub-AMC assays.
(D) In complex with GMPS the binding of the HUBL domain for GST-USP7CD increased from a Kd of 48 (±9.7) mM to 1.8 (±0.42) mM.
(E) Model for the autoactivation of the USP7 catalytic domain by the HUBL domain, which is allosterically promoted by GMPS. In its resting state, the catalytic
triad is in amisaligned and inactive conformation, resulting in an almost inactive enzyme. However, the HUBL-45 domain interacts with the USP7 catalytic domain
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acts through HUBL-45, we analyzed whether GMPS changed
the affinity of the HUBL-45 region for the catalytic domain. Strik-
ingly, whereas the HUBL-123 has no affinity for the catalytic
domain in the presence of GMPS, the dissociation constant
between the full HUBL domain and the catalytic domain
increases from 48 (±9.7) mM to 1.8 (±0.42) mM in the presence
of GMPS (Figure 7D). This shows that GMPS can allosterically
activate USP7 by binding to HUBL-123, stabilizing the contact
between HUBL-45 and USP7CD, thus promoting the activated
state.
DISCUSSION
We show here that the C-terminal HUBL-45 domain is required
and sufficient for full activity of the USP7/HAUSP deubiquitinat-
ing enzyme. This mechanism depends on contacts between the
C-terminal tail of HUBL-45 and a switching loop in the catalytic
domain, which leads to organization of the active site and an
increased affinity for ubiquitin. Single-point mutants in the
switching loop or C-terminal tail interfere with USP7 activity
in vivo and in vitro.
Apparently USP7 has the unusual ability to switch the active
site between an active and an inactive state, resulting in the
change in both kcat and KM. This was observed in the crystal
structures of the catalytic domain, with and without ubiquitin.
Most USP catalytic domains, USP8 (2GFO), USP14 (2AYN),
USP4 (2Y6E), and CYLD (2VHF), do not have this nonorganized
state of the catalytic triad. USP14 is activated by binding to the
proteasome (Leggett et al., 2002), which is mediated by a single
Ubl domain (Borodovsky et al., 2001). However, only for USP7
and Ubp8, a member of the SAGA complex, the two states are
suggested based on biochemical and structural data (Kohler
et al., 2010; Samara et al., 2010). Here we show USP7 is able
to switch, since in trans activation is possible. Apparently, the
prefolded catalytic domain can still be activated by the HUBL
domain.
At first glance, full-length USP7 is continuously in the active
state. However, we show that binding of GMPS can further acti-
vate USP7. The HUBL-123 domain, which is dispensable for
USP7 intrinsic activity, serves as a binding platform for GMPS.
This binding results in hyperactivation of USP7 through a mech-
anism that is completely dependent on a functional HUBL activa-
tion, since point mutants in this interface cannot be activated by
GMPS. Rather, GMPS binding results in an increased affinity
between the catalytic domain and the HUBL-45 unit of the
HUBL domain, stabilizing the interaction.
Therefore we propose amodel in which USP7 exists in equilib-
rium between an active and an inactive state (Figure 7E, top
panel). The switch between states involves an increase of ubiq-
uitin binding and remodeling of the active site and switching
loop, due to interactions with the HUBL-45 domain. Allosteric
interaction with GMPS stabilizes the active state, promotingand through its flexible C-terminal activating peptide mediates a conformational c
the active conformation. This increases both catalytic turnover and ubiquitin affi
vated state by binding to HUBL-123, in a mechanism that requires HUBL-45 and
unit of the HUBL domain (bottom panel).
Mothe interaction between HUBL-45 and switching loop (Figure 7E,
bottom panel). It does not affect ubiquitin binding or KM but acti-
vates through kcat, resulting in substantially more molecules in
the active state.
Since the interaction between USP7CD and the HUBL domain
is weak, and single-point mutants can completely prevent HUBL
activation, USP7 is not always in the ‘‘on’’ state but rather
displays flexibility, as seen in the SAXS experiments. That would
explain how GMPS could hyperactivate USP7 through an
increase of HUBL affinity for USP7CD, by serving as a molecular
lock to reduce HUBL flexibility.
GMPS most likely has additional target-specific regulatory
functions in cells (Sarkari et al., 2009; van der Knaap et al.,
2005). Since not all USP7 is found in complex with GMPS or
vice versa (van der Knaap et al., 2010), it is clear that USP7 is
not always in this activated state in cells.
This opens the interesting possibility that other regulators
could further modulate the interaction between the catalytic
domain and the HUBL domain, either promoting the ‘‘on state,’’
like GMPS, or by sequestering HUBL-45 from the catalytic
domain and promoting the ‘‘off-state.’’ Since USP7 is an impor-
tant player in key cellular processes, such ability to 100-fold
modulate—increase or decrease—catalytic efficiency provides
a very fast response to external stimuli. The subsequent regula-
tion could be achieved by posttranslational modification, by
interaction with other partners (Sowa et al., 2009), or even by
substrate interactions, since, e.g., MDM2 and p53 were shown
to interact with the HUBL domain.
Regulation of USP catalytic activity through allosteric interac-
tion has been observed before, e.g., for the SAGA complex,
where binding of Sgf11 is necessary to maintain the catalytic
residues of Ubp8 in the proteolytically active conformation
(Kohler et al., 2010; Samara et al., 2010). Interestingly, this
allosteric activation depends on the topologically equivalent
switching loop as in USP7. Moreover, USP7 and Upb8 share
the conserved W285 that is involved in the switching of USP7,
confirming its importance. However, the mechanism in Ubp8 is
distinct, since it relies on intermolecular interactions, rather
than an intramolecular interaction as in USP7.
Surprisingly, both the activation of USP7 and the GMPS
binding are conveyed by Ubl domains. None of these Ubl
domains seem to resemble ubiquitin enough to compete for
ubiquitin binding in the substrate binding site. This is in contrast
to the internal Ubl domain in USP4, which competitively inhibits
catalytic activity (Luna-Vargas et al., 2011). In USP7 the Ubl
domains behave as larger units, with different functions.
Although Ubl domains were predicted in other USPs, the large
number of Ubl domain in the HUBL domain itself seems to be
unique for USP7.
The importance of USP7 for localization and stability of critical
cancer targets such as FOXO4, PTEN, and p53/MDM2 makes it
into an interesting drug target. The unique features of its regula-
tion may well offer specific opportunities for drug development.hange of the switching loop, resulting in a rearrangement of the catalytic triad to
nity (top panel). Subsequent binding of GMPS allosterically stabilizes the acti-
results in an increased affinity between the catalytic domain and the HUBL-45
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Protein Expression and Purification
Full-length USP7 and GMPS were expressed in insect cells, USP7 truncation
constructs, andmutants inE. coli. Proteins were purified usingGSTSepharose
(GE Healthcare) followed by size exclusion chromatography in 10 mM HEPES
(pH 7.5), 100mMNaCl, and 1mMDTT. All proteins eluted from the gel filtration
as monomers.In Vitro p53 Deubiquitination Assay
Purified hyperstable p53 (Khoo et al., 2009) was ubiquitinated for 1 hr at 37C.
The reaction was stopped by adding 11 mM EDTA and incubated with varying
concentrations of USP7 for 1 hr at 37C. Western blot was performed using
mouse p53 antibody (PAB240 Santa Cruz).Cell Cultures, Transient Transfections
U2OS cells were transfected with 10 mg of the GFP-USP7 construct and 0.5 mg
pBabePuro per 10 cm dish. Forty-eight hours after transfection, cells were
selected with puromycin. Western blots were performed using whole-cell
extracts transferred to PVDF membranes (Millipore).Kinetic Analysis with Ubiquitin-AMC Assay
Kinetic parameters were determined using constant enzyme concentrations
(1 nM for fully active USP7, else 10 nM) to hydrolyze varying substrate concen-
trations (from 15 mM in 2-fold dilutions). Curves were obtained by plotting
enzyme initial rates (v) versus substrate concentrations ([S]) and were sub-
jected to nonlinear regression fit using the Michaelis-Menten equation. Exper-
imental data were processed using Prism 4.03 (GraphPad Software, Inc.).Crystal Structure Determination
For data collection statistics and crystallographic parameters, see Table 1.
HUBL was crystallized at 4C in sitting drops against 10% (w/v) PEG4000,
200 mM sodium chloride, and 100 mM MES at pH 6.0 and supplemented
with 20% (w/v) glycerol as cryoprotectant. Diffraction images were integrated
with iMOSFLM (Leslie, 2006) and scaled with SCALA (Evans, 2006). Structure
was solved from a selenomethionine derivative, using SHARP/autoSHARP
(Vonrhein et al., 2007). ARP/wARP (Langer et al., 2008) traced 375 out of
547 residues. This model was manually completed in Coot (Emsley and
Cowtan, 2004) and refined in iterative cycles with PHENIX (Adams et al.,
2010) and Buster (Blanc et al., 2004).SAXS Sample Preparation, Data Collection, and Analysis
Samples for the SAXS experiments were prepared fresh, and five samples
were taken during concentration (from 0.5 to 10 mg/ml), collecting the
flowthrough for blank measurements. Data were analyzed using the ATSAS
software package (Svergun et al., 2001). For the HUBL domain, aggregation
was observed and only the lowest concentration was used.Surface Plasmon Resonance
SPR was performed at 25C on a Biacore T100. A CM5 sensor chip was
prepared with monoclonal GST antibody via amino coupling. Biotinylated
peptides were coupled to a SA chip. Saturation binding values were plotted
against concentration USP7 (GST as reference) and fit to a steady-state affinity
model for calculation of apparent dissociation (Kd) constants (Prism 4.03,
GraphPad Software, Inc.). All experiments have been repeated at least three
times.
Extended experimental procedures are presented in the Supplemental
Information.ACCESSION NUMBERS
Coordinates and structure factors were deposited in the Protein Data Bank
under identification code 2YLM.158 Molecular Cell 44, 147–159, October 7, 2011 ª2011 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.molcel.2011.06.034.
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